FDA Keeps Its Focus on Provenge With “Untitled” Letter For Promotional Violations
This article was originally published in The Pink Sheet Daily
Executive Summary
CBER’s Office of Compliance and Biologics Quality says marketing pieces omit and minimize risk information about sterility testing and overstate survival efficacy.